TROY, NY, UNITED STATES, February 5, 2026 /EINPresswire.com/ — Inspect Point, the leading SaaS platform for fire and life safety inspection, testing, and compliance ...
Investor's Business Daily on MSN
Dyne Therapeutics trades sideways over an FDA hurdle. Is it time to take profits?
Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients.
Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results